NASDAQ:STIMNeuronetics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Neuronetics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.75 +0.11 (+6.71 %) (As of 04/8/2020 03:19 PM ET) Add Compare Share Today's Range$1.64Now: $1.75▼$1.7650-Day Range$1.28MA: $2.23▼$3.4052-Week Range$1.25Now: $1.75▼$17.76Volume3,278 shsAverage Volume289,739 shsMarket Capitalization$32.67 millionP/E RatioN/ADividend YieldN/ABeta1.15 ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrist customers. Neuronetics, Inc. was founded in 2003 and is headquartered in Malvern, Pennsylvania.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingNeuronetics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.50, Neuronetics has a potential upside of 385.7% from its current price of $1.75.Amount of Analyst CoverageNeuronetics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesNeuronetics has received 99 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNeuronetics has received 92 “underperform” votes. (Add your “underperform” vote.)Community SentimentNeuronetics has received 51.83% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Neuronetics and other stocks. Vote “Outperform” if you believe STIM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe STIM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNeuronetics does not currently pay a dividend.Dividend GrowthNeuronetics does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neuronetics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $93,600.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 12.00% of the stock of Neuronetics is held by insiders.Percentage Held by Institutions70.80% of the stock of Neuronetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Neuronetics are expected to decrease by -13.42% in the coming year, from ($1.49) to ($1.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neuronetics is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neuronetics is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuronetics has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.15 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:STIM Previous Symbol CUSIPN/A CIKN/A Webhttp://www.neurostar.com/ Phone610-640-4202Debt Debt-to-Equity Ratio0.47 Current Ratio3.19 Quick Ratio3.09Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$62.66 million Price / Sales0.52 Cash FlowN/A Price / Cash FlowN/A Book Value$2.57 per share Price / Book0.68Profitability EPS (Most Recent Fiscal Year)($1.58) Net Income$-29,040,000.00 Net Margins-46.35% Return on Equity-51.08% Return on Assets-27.11%Miscellaneous Employees191 Outstanding Shares18,670,000Market Cap$32.67 million Next Earnings Date5/5/2020 (Estimated) OptionableNot Optionable Receive STIM News and Ratings via Email Sign-up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:STIM Rates by TradingView Neuronetics (NASDAQ:STIM) Frequently Asked Questions How has Neuronetics' stock been impacted by COVID-19 (Coronavirus)? Neuronetics' stock was trading at $2.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, STIM shares have decreased by 15.5% and is now trading at $1.75. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Neuronetics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Neuronetics. When is Neuronetics' next earnings date? Neuronetics is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Neuronetics. How were Neuronetics' earnings last quarter? Neuronetics Inc (NASDAQ:STIM) issued its quarterly earnings results on Tuesday, March, 3rd. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.44) by $0.03. The company had revenue of $17.36 million for the quarter, compared to analyst estimates of $17 million. Neuronetics had a negative return on equity of 51.08% and a negative net margin of 46.35%. View Neuronetics' earnings history. What guidance has Neuronetics issued on next quarter's earnings? Neuronetics updated its FY 2020 Pre-Market earnings guidance on Tuesday, March, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $69-71 million, compared to the consensus revenue estimate of $70.56 million. What price target have analysts set for STIM? 3 brokerages have issued twelve-month price targets for Neuronetics' stock. Their forecasts range from $6.00 to $11.00. On average, they expect Neuronetics' share price to reach $8.50 in the next year. This suggests a possible upside of 385.7% from the stock's current price. View analysts' price targets for Neuronetics. Has Neuronetics been receiving favorable news coverage? News stories about STIM stock have been trending very negative recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Neuronetics earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutNeuronetics. Are investors shorting Neuronetics? Neuronetics saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 442,700 shares, an increase of 12.8% from the February 13th total of 392,500 shares. Based on an average daily volume of 211,500 shares, the short-interest ratio is currently 2.1 days. Currently, 5.6% of the shares of the stock are sold short. View Neuronetics' Current Options Chain. Who are some of Neuronetics' key competitors? Some companies that are related to Neuronetics include Apyx Medical (APYX), RenovaCare (RCAR), TELA Bio (TELA), AIT Therapeutics (AITB), Spectral Medical (EDTXF), BRAINSWAY LTD/S (BWAY), PAVmed (PAVM), Pro-Dex (PDEX), SANUWAVE Health (SNWV), Nephros (NEPH), Nephros (NEPHD), Apollo Endosurgery (APEN), Delcath Systems (DCTH), Sensus Healthcare (SRTS) and Arch Therapeutics (ARTH). What other stocks do shareholders of Neuronetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Tonix Pharmaceuticals (TNXP), Onconova Therapeutics (ONTX), Actinium Pharmaceuticals (ATNM), Aquestive Therapeutics (AQST), Biocept (BIOC), Gilead Sciences (GILD), Novavax (NVAX) and Ocular Therapeutix (OCUL). Who are Neuronetics' key executives? Neuronetics' management team includes the following people: Mr. Christopher A. Thatcher, CEO, Pres & Director (Age 54)Mr. Peter L. Donato, CFO, VP & Corp. Sec. (Age 49)Mr. Gregory Harper, VP of R&D, Operations and Product Devel. (Age 58)Ms. Cassie Hallberg, VP of MarketingMr. Daniel Guthrie, Chief Commercial Officer & VP (Age 42) When did Neuronetics IPO? (STIM) raised $75 million in an IPO on Thursday, June 28th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and William Blair acted as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers. What is Neuronetics' stock symbol? Neuronetics trades on the NASDAQ under the ticker symbol "STIM." How do I buy shares of Neuronetics? Shares of STIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Neuronetics' stock price today? One share of STIM stock can currently be purchased for approximately $1.75. How big of a company is Neuronetics? Neuronetics has a market capitalization of $32.67 million and generates $62.66 million in revenue each year. The company earns $-29,040,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis. Neuronetics employs 191 workers across the globe. View additional information about Neuronetics. What is Neuronetics' official website? The official website for Neuronetics is http://www.neurostar.com/. How can I contact Neuronetics? Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The company can be reached via phone at 610-640-4202 or via email at [email protected] This page was last updated on 4/8/2020 by MarketBeat.com StaffFeatured Article: Pattern Day Trader - What is the PDT Rule?
